Department of Clinical Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Department of Radiotherapy, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iran J Med Sci. 2023 Sep;48(5):456-464. doi: 10.30476/IJMS.2022.95039.2673.
The association between metabolic syndrome (MetS) and breast cancer may significantly impact the mortality and incidence of breast cancer. This study aimed to assess the association between MetS risk factors and immunohistochemical (IHC) profiles in women with breast cancer.
This cross-sectional study used the medical records of 300 breast cancer patients with an average age of 53.11±12.97 years in the Chemotherapy and Radiation Therapy Clinic of Dr. Anbiai, Tehran, Iran (2020-2021). The cases were divided into five subgroups including luminal A, luminal B (HER-2), luminal B (HER-2), HER-2 overexpressing, and triple negative.
There was no difference in the prognostic indicators between the presence and absence of MetS in women with breast cancer. A higher proportion of luminal A tumors (39.3%), luminal B (HER-2) (25%), triple-negative (17%), luminal B (HER-2) (10.7%), HER-2 overexpression (8%) was observed in women with MetS than those without MetS. Multivariate logistic regression analysis showed that patients with MetS had a 41% higher chance of developing luminal A than those without MetS, and patients with a BMI≥30 Kg/m had an 80% higher chance of developing luminal B (HER-2) than those with a BMI<30 Kg/m. Moreover, women with a waist circumference higher than 88 cm had a 14 % lower chance of developing Luminal B (HER-2) than those with a waist circumference less than 88 cm.
There was no difference in prognostic indicators and IHC profile in patients with and without MetS.
代谢综合征（MetS）与乳腺癌之间的关联可能会显著影响乳腺癌的死亡率和发病率。本研究旨在评估乳腺癌患者中 MetS 危险因素与免疫组织化学（IHC）特征之间的关系。
本横断面研究使用了伊朗德黑兰 Anbiai 博士化疗和放疗诊所 300 名平均年龄为 53.11±12.97 岁的乳腺癌患者的病历（2020-2021 年）。这些病例分为五个亚组，包括 luminal A、luminal B（HER-2）、luminal B（HER-2）、HER-2 过表达和三阴性。
在患有乳腺癌的女性中，MetS 的存在与否与预后指标无差异。患有 MetS 的女性中 luminal A 肿瘤（39.3%）、luminal B（HER-2）（25%）、三阴性（17%）、luminal B（HER-2）（10.7%）和 HER-2 过表达（8%）的比例较高，而无 MetS 的女性则较低。多变量逻辑回归分析显示，患有 MetS 的患者发生 luminal A 的可能性比无 MetS 的患者高 41%，BMI≥30 Kg/m 的患者发生 luminal B（HER-2）的可能性比 BMI<30 Kg/m 的患者高 80%。此外，腰围大于 88 cm 的女性发生 luminal B（HER-2）的可能性比腰围小于 88 cm 的女性低 14%。
患有或不患有 MetS 的患者的预后指标和 IHC 特征无差异。
